Journal of Clinical Oncology
Articles in this Issue
Impact of SGLT2i and GLP1 agonists on prostate cancer incidence and outcomes: A real-world propensity score–matched cohort study.
e17148 Background: Prior studies have shown a decreased incidence of PCa in males with type two diabetes mellitus (TIIDM)...
The association of economic measures and patient outcomes with geographical disparities in access to a UCNS board-certified neuro-oncologist in the United States.
2039 Background: Neuro-oncology is increasingly centralized in academic tertiary centers, potentially creating geographic...
Early lipid-lowering therapy initiation after lorlatinib and clinical outcomes in non–small cell lung cancer: A propensity-matched real-world analysis.
8597 Background: Lorlatinib improves outcomes in NSCLC but commonly causes marked hyperlipidemia, prompting initiation of...
Artificial intelligence and obesity-related factors in breast cancer outcomes: A systematic review and pooled meta-analysis.
e12573 Background: Obesity and excess adiposity are established contributors to breast cancer risk, tumor biology, and tre...
Luvometinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: A randomized, double-blind, placebo-controlled, phase 3 trial.
3017 Background: Neurofibromatosis type 1 (NF1) related plexiform neurofibromas (PNs) is associated with significant morbi...
Reprogramming tumor-associated immune cells with Z-007, a first-in-class systemic TLR7/8/9 agonist.
e14565 Background: Overcoming tumor-mediated immune suppression is a critical barrier in cancer immunotherapy. Anti-tumor...
A new HLA genotyping algorithm to show accuracy and concordance between tumor and normal samples.
2584 Background: HLA genotyping, specifically HLA-A*02:01 is an actionable marker in uveal melanoma for Tebentafusp, a bis...
ASTRON (OGSG 2401): A multicenter prospective trial of ferric carboxymaltose without erythropoiesis-stimulating agents for iron deficiency anemia in patients with gastric/colorectal cancer receiving chemotherapy.
12045 Background: Iron deficiency anemia (IDA) during chemotherapy for patients with gastrointestinal cancer worsens quali...
First-line rilvegostomig (R) + chemotherapy (CTx) in advanced biliary tract cancer (BTC): Updated analysis of GEMINI-Hepatobiliary substudy 2 cohort A.
4105 Background: Addition of PD-(L)1 inhibitors to CTx has transformed advanced BTC treatment but survival is limited for...
Deciphering the heterogeneity and cellular interactions of cancer-associated fibroblasts in extrahepatic cholangiocarcinoma by spatial transcriptomics.
4237 Background: Cholangiocarcinoma (CCA) is a rare and lethal malignancy characterized by a desmoplastic stroma. containi...
Efficacy and safety of larotrectinib in patients with non-primary central nervous system <i>TRK</i> fusion cancer: An updated analysis.
3145 Background: Larotrectinib (laro) is the first-in-class, highly selective TRK inhibitor approved for tumor-agnostic us...
Efficacy and safety results of a first-in-class PRMT1 inhibitor CTS2190 in patients (pts) with immune checkpoint inhibitor (ICI)–insensitive advanced solid tumors.
e15164 Background: Immuno-cold tumors remain low response rate to ICIs. The treatment options and efficacy are limited for...
Primary care (PCP) and oncology (ONC) provider perspectives on primary care involvement in cancer clinical trial discussions in a safety-net health system.
e13592 Background: A collaborative model of care between PCPs and ONCs within safety-net systems may be needed to increase...
Advancing value-based breast cancer screening in a safety-net health system: A multimodal approach to improving population health and system sustainability.
11114 Background: Evaluation of breast cancer screening (BCS) adherence in our large safety-net health system revealed wid...
Prognostic impact of ASXL1 somatic mutation on patients with chronic myeloid leukemia: A systemic review and meta-analysis.
e18596 Background: Outcomes in chronic myeloid leukemia (CML) remain heterogeneous despite effective BCR::ABL1 tyrosine ki...
Trastuzumab deruxtecan (T-DXd) + bevacizumab (BEV) as first-line (1L) maintenance therapy in patients (pts) with human epidermal growth factor receptor 2 (HER2)–expressing ovarian cancer (OC): Results from the DESTINY-Ovarian01 (DO-01/ENGOT-ov89/GOG-3112/APGOT-OV13) safety run-in (SRI).
5554 Background: HER2 immunohistochemistry (IHC) expression scores of 3+, 2+, or 1+ occur in up to ~6%, ~28%, and ~21% of...
Diagnostic performance, safety, and biodistribution of [ <sup>68</sup> Ga]Ga-OncoACP3 for PET imaging in prostate cancer: A phase I clinical trial.
3074 Background: Acid Phosphatase 3 (ACP3) is an emerging promising theranostic target in prostate cancer (PCa), expressed...
RNA expression signatures as predictors of prognosis in thin and thick primary cutaneous melanoma.
e21602 Background: Risk stratification of primary cutaneous melanoma based on Breslow thickness remains clinically imperfe...
mRNA profiles to identify metaphase, histone, and cancer testis antigen gene overexpression in metastatic GEP-NETs: An ORIEN analysis.
e16313 Background: Well-differentiated GEP-NETs comprise a heterogenous group of malignancies with variable behavior. Whil...
Using machine learning to predict treatment delivery accuracy in brain stereotactic radiosurgery.
e14007 Background: Accurate dose delivery in SRS is critical when treating small intracranial targets near critical struct...
Re-evaluating pathologic response as a surrogate endpoint after neoadjuvant immune checkpoint inhibition in resectable mucosal HNSCC: Updated systematic review and meta-analysis.
e18078 Background: Neoadjuvant immune checkpoint inhibition (ICI) is increasingly studied in resectable mucosal head and n...
Peri-operative nab-paclitaxel with sequential radiotherapy in cardiac angiosarcoma: A single-center retrospective cohort study.
e23549 Background: Primary cardiac angiosarcoma (PCA) is an extremely rare and highly aggressive soft-tissue sarcoma. Due...
Decoding BTN3A3: A potential biomarker and therapeutic target to promote glycolytic metabolism reprogramming and nasopharyngeal carcinoma progression.
e15193 Background: Butyrophilin subfamily 3 member A3 (BTN3A3) is expressed in various tumors, where it modulates glycolys...
ReDiscover-2, a phase 3 study of zovegalisib (zovega, RLY-2608) + fulvestrant (fulv) versus capivasertib (capi) + fulv as treatment for locally advanced or metastatic <i>PIK3CA</i> -mutant HR+/ HER2- breast cancer following recurrence or progression on or after treatment with a CDK4/6 inhibitor.
TPS1148 Background: PIK3CA mutations constitutively activate PI3Kα and drive ~40% of HR+/HER2- breast...
Prenatal hormonal imprinting reflected by anogenital distance and risk of breast cancer: A case-control study of 839 women.
10554 Background: Anogenital distance (AGD) is a sexually dimorphic, stable anthropometric marker set during fetal develop...